The Europe Sequencing Reagents Market is expected to witness market growth of 17.0% CAGR during the forecast period (2024-2031).
The Germany market dominated the Europe Sequencing Reagents Market by country in 2023, and is expected to continue to be a dominant market till 2031; thereby, achieving a market value of $1.32 billion by 2031. The UK market is exhibiting a CAGR of 16% during 2024-2031. Additionally, the France market is expected to experience a CAGR of 18% during 2024-2031.
The sequencing reagents market has emerged as a critical component of the rapidly advancing field of genomics, pivotal in enabling cutting-edge research, clinical diagnostics, and therapeutic innovations. These reagents are the foundation of genomic sequencing workflows, facilitating processes such as DNA and RNA extraction, library preparation, amplification, and sequencing. With the focus on understanding the genetic underpinnings of diseases and biological systems, the demand for high-quality sequencing reagents continues to grow exponentially.
Additionally, the evolution of sequencing technologies has been a driving force behind the expanding market for sequencing reagents. From the early days of Sanger sequencing to the widespread adoption of next-generation sequencing (NGS) and third-generation sequencing technologies, advancements in accuracy, speed, and cost-effectiveness have transformed the genomics landscape.
The sequencing reagents market in Europe is characterized by its diverse applications and strong government support across various nations. Pharmaceutical and biotechnology companies across Europe are major contributors to the demand for sequencing reagents, as they integrate genomic data into drug discovery and development processes. Companies like AstraZeneca, Novartis, and Roche utilize sequencing to identify biomarkers, validate drug targets, and conduct pharmacogenomic studies. Government programs like the European Innovative Medicines Initiative (IMI) encourage collaboration between the public and private sectors, fostering the use of sequencing technologies in pharmaceutical R&D.
The Germany market dominated the Europe Sequencing Reagents Market by country in 2023, and is expected to continue to be a dominant market till 2031; thereby, achieving a market value of $1.32 billion by 2031. The UK market is exhibiting a CAGR of 16% during 2024-2031. Additionally, the France market is expected to experience a CAGR of 18% during 2024-2031.
The sequencing reagents market has emerged as a critical component of the rapidly advancing field of genomics, pivotal in enabling cutting-edge research, clinical diagnostics, and therapeutic innovations. These reagents are the foundation of genomic sequencing workflows, facilitating processes such as DNA and RNA extraction, library preparation, amplification, and sequencing. With the focus on understanding the genetic underpinnings of diseases and biological systems, the demand for high-quality sequencing reagents continues to grow exponentially.
Additionally, the evolution of sequencing technologies has been a driving force behind the expanding market for sequencing reagents. From the early days of Sanger sequencing to the widespread adoption of next-generation sequencing (NGS) and third-generation sequencing technologies, advancements in accuracy, speed, and cost-effectiveness have transformed the genomics landscape.
The sequencing reagents market in Europe is characterized by its diverse applications and strong government support across various nations. Pharmaceutical and biotechnology companies across Europe are major contributors to the demand for sequencing reagents, as they integrate genomic data into drug discovery and development processes. Companies like AstraZeneca, Novartis, and Roche utilize sequencing to identify biomarkers, validate drug targets, and conduct pharmacogenomic studies. Government programs like the European Innovative Medicines Initiative (IMI) encourage collaboration between the public and private sectors, fostering the use of sequencing technologies in pharmaceutical R&D.
List of Key Companies Profiled
- Agilent Technologies, Inc.
- F.Hoffmann-La Roche Ltd.
- Danaher Corporation (Beckman Coulter, Inc.)
- Abbott Laboratories
- Bio-Rad Laboratories, Inc.
- Quest Diagnostics Incorporated
- Revvity, Inc.
- Eurofins Scientific SE
- Hologic, Inc.Illumina, Inc.
Market Report Segmentation
By Type
- Sequencing Kits
- Library Kits
- Control Kits
- Template Kits
- Other Type
By Technology
- Next-Generation Sequencing
- Third Generation Sequencing
- Sanger Sequencing
By Application
- Oncology
- Reproductive Health
- Clinical Investigation
- Agrigenomics & Forensics
- Consumer Genomics
- Other Application
By End Use
- Academic Research
- Clinical Research
- Hospitals & Clinics
- Pharmaceutical & Biotechnology Companies
- Other End Use
By Country
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. Competition Analysis - Global
Chapter 5. Europe Sequencing Reagents Market by Type
Chapter 6. Europe Sequencing Reagents Market by Technology
Chapter 7. Europe Sequencing Reagents Market by Application
Chapter 8. Europe Sequencing Reagents Market by End Use
Chapter 9. Europe Sequencing Reagents Market by Country
Chapter 10. Company Profiles
Companies Mentioned
- Agilent Technologies, Inc.
- F. Hoffmann-La Roche Ltd.
- Danaher Corporation (Beckman Coulter, Inc.)
- Abbott Laboratories
- Bio-Rad Laboratories, Inc.
- Quest Diagnostics Incorporated
- Revvity, Inc.
- Eurofins Scientific SE
- Hologic, Inc.
- Illumina, Inc.
Methodology
LOADING...
